))
Advancements in Heart Failure Clinical Research
Manage episode 425413603 series 2849626
Innehåll tillhandahållet av BEaTS Research Radio. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av BEaTS Research Radio eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Nicole Chu from the University of Ottawa speaks with Dr. Javed Butler. Dr. Javed Butler, MD, MPH, MBA, is the President of the Baylor Scott and White Research Institute, and Senior Vice President and Maxwell A. and Gayle H. Clampitt Endowed Chair at the Baylor Scott and White Health in Dallas, Texas. He is also the Distinguished Professor of Medicine at the University of Mississippi in Jackson, Mississippi. In this episode, Dr. Butler shares with us the major findings from the recent EMPACT-MI clinical trial and his perspective on the future of heart failure therapies. The EMPACT-MI trial investigated whether a medicine called empagliflozin, a SGLT2 inhibitor, helps to lower the risk of heart failure and death in people had experienced a heart attack (myocardial infarction).
Learn more about the EMPACT-MI clinical trial https://www.nejm.org/doi/full/10.1056/NEJMoa2206286
31 episoder
Dela
